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ABSTRACT
Obesity and diabetes have been associated with increased risk and worse 
outcomes in ovarian cancer (OC). The biguanide metformin is used in the treatment 
of type 2 diabetes and is also believed to have anti-tumorigenic benefits. Metformin 
is highly hydrophilic and requires organic cation transporters (OCTs) for entry into 
human cells. Phenformin, another biguanide, was taken off the market due to an 
increased risk of lactic acidosis over metformin. However, phenformin is not reliant 
on transporters for cell entry; and thus, may have increased potency as both an anti-
diabetic and anti-tumorigenic agent than metformin. Thus, our goal was to evaluate 
the effect of phenformin on established OC cell lines, primary cultures of human OC 
cells and in an orthotopic mouse model of high grade serous OC. In three OC cell lines, 
phenformin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and 
apoptosis, caused cellular stress, inhibited adhesion and invasion, and activation of 
AMPK and inhibition of the mTOR pathway. Phenformin also exerted anti-proliferative 
effects in seven primary cell cultures of human OC. Lastly, phenformin inhibited tumor 
growth in an orthotopic mouse model of serous OC, coincident with decreased Ki-67 
staining and phosphorylated-S6 expression and increased expression of caspase 3 and 
phosphorylated-AMPK. Our findings demonstrate that phenformin has anti-tumorigenic 
effects in OC as previously demonstrated by metformin but it is yet to be determined 
if it is superior to metformin for the potential treatment of this disease.
INTRODUCTION
Ovarian cancer (OC) is one of the leading causes 
of cancer related deaths among women worldwide with 
an overall 5-year survival of only 30-40% [1]. Increasing 
evidence suggests that obesity is a significant risk factor 
for OC and is associated with worse outcomes for this 
disease [2–9]. Obesity has reached epidemic proportions 
in the United States, with over 30% of adults considered 
obese and 65% considered overweight based on their 
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body mass index (BMI) [10]. Impaired glucose regulation 
and insulin resistance are consequences of obesity, 
often culminating in Type II diabetes. Type II diabetes 
in addition to obesity appears to affect OC survival. A 
recent study of 642 women with OC over a 10-year period 
found a significantly worse overall survival in diabetics 
as compared to non-diabetics, even after multivariable 
adjustment [11].
Overweight and obese states may be linked to OC 
through nutrient sensitive signaling cascades, such as the 
insulin/insulin growth factor (IGF) and PI3K/Akt/mTOR 
pathways [12]. Hyperinsulinemia, IGF-1, and IGF-1 
receptor (IGF-1R) levels are known to be important in OC 
development and progression [13–15]. Signaling through 
IGF-1R leads to activation of the downstream PI3K/Akt/
mTOR pathway, and components of this pathway are 
often mutated, amplified or aberrantly expressed in OCs 
[16, 17]. In addition, our previous work found that the 
metabolic effects of obesity promoted OC progression and 
aggressiveness in a genetically engineered mouse model of 
high grade serous OC [18]. Therefore, a metabolic approach 
to the treatment of OC may provide a novel strategy to 
improve outcomes for this invariably lethal disease.
Metformin, a biguanide drug, is one of the most 
widely prescribed treatments for Type II diabetes. 
Epidemiological evidence suggests that metformin 
lowers cancer risk and reduces cancer incidence and 
deaths among diabetic patients [19–21], including OC 
[22–26]. Pre-clinical studies have reported that metformin 
causes disruption of mitochondrial respiration leading to 
activation of AMP-activated protein kinase (AMPK) and 
inhibition of the mTOR pathway, ultimately decreasing 
cell proliferation, adhesion, migration and angiogenesis 
in OC cell lines and animal models [27–36]. Currently, 
metformin is being investigated in greater than 50 phase 
I, II and III clinical trials in a number of different cancers, 
including OC [37].
Phenformin is another biguanide with anti-
diabetic activity. Phenformin is almost 50 times as 
potent as metformin for the treatment of diabetes, but it 
was withdrawn from the market in the United States in 
1977 due to a small increased risk of lactic acidosis (64 
cases per 100,000 patient-years), higher than that seen 
with metformin (3 in 100,000 years) [38]. Metformin 
is highly hydrophilic with a net positive charge at all 
physiologic pH values. Therefore, it requires cation-
selective transporter proteins that mediate its entry into 
cells, including OCT1-3, PMAT and MATE 1-2 [39]. 
Phenformin is more lipophilic and is not reliant on these 
transporter proteins, allowing for higher concentrations 
of this biguanide over metformin to accumulate 
intracellularly. It has been theorized that phenformin 
may have heightened anti-tumorigenic efficacy as 
compared to metformin, due to increased uptake of this 
drug by tumor cells. In vitro and in vivo studies in breast, 
prostate, lung, melanoma, glioblastoma and colon cancer 
demonstrate that phenformin is more potent for inhibiting 
cell proliferation and tumor growth than metformin [40–
46]. Compared to metformin, phenformin has also been 
shown to be a more potent inhibitor of mitochondrial 
complex I, which causes overproduction of reactive 
oxygen species [47]. Thus, our objective was to evaluate 
the potential anti-tumorigenic effects of phenformin in 
OC cell lines, primary cultures of human OC cells and 
in an orthotopic mouse model of high grade serous OC. 
Our hypothesis was that phenformin would demonstrate 
anti-tumorgenic effects similar to metformin in OC. Our 
results showed that phenformin is a promising agent to 
inhibit cell proliferation and tumor growth in OC cell 
lines, primary cultures of human OC and in an orthotopic 
mouse model of high grade serous OC.
RESULTS
Phenformin inhibits cell proliferation in OC cells
The effect of phenformin on OC cell proliferation 
was assessed by MTT assay. Three OC cell lines, 
SKOV3, Hey and IGROV-1, were treated with varying 
concentrations of phenformin for 72 hours. As shown in 
Figure 1A, phenformin inhibited cell proliferation of all 
three OC cell lines in a dose-dependent manner after 72 
hours of treatment. The mean IC50 value for SKOV3, Hey 
and IGROV-1 was 0.9, 1.75 and 0.8 mM, respectively. 
These results suggest that phenformin effectively 
inhibits cell proliferation in OC cells. Successively, we 
compared the effect of phenfornin and metformin on 
cell proliferation in all three OC cell lines. We observed 
that both phenformin and metformin exhibited inhibitory 
effects on cell proliferation after 72 hours of treatment. 
However, phenformin at either low or high dosages was 
found to significantly increase the growth inhibition in the 
OC cell lines compared to metformin (Figure 1B). These 
results suggest that phenformin appeared more potent than 
metformin in inhibition of cell proliferation.
Given that biguanide is transported into cells by 
organic cation transporters (OCTs) 1, 2, and 3, we next 
investigated the affinity of phenformin and metformin 
for OCT1, OCT2 and OCT3/4 in the SKOV3, Hey and 
IGROV-1 cells. We treated three cell lines with 0.1 
and 1 mM phenformin and metformin for 24 hours, 
respectively. Either metformin or phenformin decreased 
OCT1 and OCT3/4 expression in the OC cells, with the 
greatest effects seen in three cell lines after exposure to 
1 mM phenformin. Phenformin and metformin did not 
affect OCT2 expression in all three cell lines (Figure 1C). 
These results when compared to metformin demonstrate 
that phenoformin may have enhanced affinity for OCT1 
and OCT3 and improved potency over metformin in 
expression of OCT1 and OCT3.
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Phenformin induces cell cycle arrest and 
apoptosis
To evaluate the underlying mechanism of growth 
inhibition by phenformin, the cell cycle profile was analyzed 
after treating the SKOV3, Hey and IGROV-1 cell lines with 
varying doses (0.01-2.5 mM) of phenformin for 24 hours. 
As illustrated in Figure 2A, phenformin induced G0/G1 cell 
cycle arrest and reduced S phase in the Hey and SKOV3 
OC cell lines and increased G2 phase in the IGROV-1 OC 
cell line in a dose-dependent manner. These results suggest 
that phenformin induced cell cycle arrest through different 
checkpoints among the three OC cell lines.
To further characterize phenformin’s effect on cell 
cycle arrest, cell cycle-related proteins were analyzed in 
the phenformin-treated SKOV3, Hey and IGROV-1 cell 
lines. Western immunoblotting showed that phenformin 
down-regulated the cell cycle related proteins, cyclin D 
and CDK4 and increased p21 expression (Figure 2B). The 
effect of phenformin on apoptosis was evaluated using 
the Annexin V assay. This assay detects apoptotic cells 
by monitoring fluorescently labeled Annexin V, which 
binds to phosphatidylserine externalized on the surface 
of the cell membrane and is representative of a distinct 
phenomenon of early apoptosis. All cell lines were treated 
with phenformin at varying concentrations (0.01-1 mM) 
for 18 hours. The percentage of apoptotic cells increased 
distinctly in a dose-dependent manner in the Hey and 
IGROV-1 cell lines whereas phenformin had no effect 
on annexin V expression in the SKOV3 cells (Figure 
2C). These results suggest that phenformin inhibits cell 
proliferation through divergent mechanisms in OC cells.
Figure 1: Effect of phenformin on cell proliferation in the OC cells. The SKOV3, Hey and IGROV-1 cell lines were cultured in 
the presence of varying concentrations of phenformin for 72 hours. Cell proliferation was determined by MTT assay. (A) The comparison 
of metformin and phenformin in inhibition of cell proliferation was assessed after 72 hours of treatment. (B) The effect of metformin and 
phenformin on OCT1, OCT2 and OCT3/4 on ovarian cancer cells was assayed by western blotting. (C) The results are shown as the mean 
± SE of triplicate samples and are representative of three independent experiments.
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Effect of phenformin on the AMPK/mTOR 
pathway
It is well known that AMPK and the mTOR pathway 
play a crucial role in the control of cell growth survival in 
OC, and targeting of these pathways leads to the inhibition 
of OC growth [48]. To investigate the mechanisms 
underlying the inhibition of ovarian cell growth by 
phenformin, we characterized the effect of phenformin 
on its immediate downstream signaling target, AMPK. 
Previous studies suggest that p70S6K is a downstream 
target of the mTOR pathway [49]. p70S6K kinase directly 
phosphorylates the 40S ribosomal protein S6, which 
results in enhanced translation of proteins that contain a 
polypyrimidine tract in the 5’-untranslated region [49]. 
Therefore, we studied the effect of phenformin on the 
phosphorylation of the S6 ribosomal protein and AMPK 
in all three cell lines. As expected, phenformin increased 
phosphorylation of AMPK and decreased phosphorylation 
of S6 in all three OC cell lines, within 24 hours of 
exposure (Figure 3). In addition, pan-S6 was decreased 
by phenformin in all three OC cell lines. Expression 
of pan-AMPK in the SKOV3 cells was not affected by 
phenformin.; however, an increase in pan-AMPK was 
seen in the Hey and IGROV-1 cell lines. This suggests 
that phenformin may exert its anti-proliferative effects 
through activation of AMPK and subsequent decreased 
phosphorylation of the S6 protein, resulting in inhibition 
of the mTOR pathway.
Phenformin induces cellular stress in ovarian 
cancer cells
Reactive oxygen species (ROS) have long been 
known to be a component of the cellular response to stress 
and production of ROS by diverse anti-cancer drugs has been 
closely related with the induction of apoptosis in cancers. 
Metformin has been shown to induce cell stress in different 
types of cancer [50]. To investigate the involvement of 
oxidative stress in the anti-proliferative effect of phenformin, 
intracellular ROS levels were examined using the ROS 
fluorescence indicator DCF-DA. Phenformin (0.01-2.5 mM) 
significantly increased ROS production in a dose-dependent 
manner in the OC cells after 24 hours of treatment (Figure 
Figure 2: Effect phenformin on cell cycle progression and apoptosis in the OC cells. The cells were treated with phenformin 
at different doses for 24 hours, and changes in cell cycle progression was analyzed by Cellometer. Phenformin induced G1 cell cycle arrest 
in the Hey and SKOV3 cell lines and G2 arrest in the IGROV-1 cell line. (A) Western blotting results showed that phenformin decreased 
CDK4 and cyclin D1 expression and increased p21 expression in all three cell lines. (B) The Hey, IGROV-1 and SKOV3 cells were grown 
for 24 hours and then treated with phenformin at the indicated concentrations for an additional 18 hours. Annexin V expression was detected 
by Cellometer. Phenformin induced apoptosis in the Hey and IGROV-1 cell lines, but not in the SKOV3 cell line. (C) The results are shown 
as the mean SD and are representative of three independent experiments.
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4A). We next examined the alternations of endoplasmic 
reticulum (ER) stress-related markers after treatment of 
phenoformin for 24 hours in the OC cells. Western blotting 
results showed that phenformin significantly induced the 
protein expression of PERK, Ero1-Lα and PDI in a dose 
dependent manner (Figure 4B). These results indicate that 
an increase in ROS production and ER stress might also be 
involved in the anti-tumorigenic effects of phenformin in 
ovarian cancer cells.
Phenformin inhibits cell adhesion and invasion 
in ovarian cancer cells
Adhesion and invasion are important steps leading 
to metastasis in ovarian cancer. In order to determine the 
effect of phenformin on adhesion and invasion of ovarian 
cancer cells, an in vitro laminin adhesion assay and 
transwell invasion system were employed, respectively. 
Incubation of the OC cell lines with phenformin at 0.1 
and 2.5 mM for 2 hours showed a significant reduction in 
adhesion ( IGROV-1 in 5-17%, Hey cells in 9-23% and 
SKOV3 cells in 6-34%, p<0.05) (Figure 5A). Phenformin 
significantly blocked cell invasion after 24 hours of 
treatment in the OC cell lines (IGROV-1 in 17-25%, Hey 
cells in 20-29% and SKOV3 cells in 10-18%, p<0.05), 
as determined by the transwell invasion assay (Figure 
5B). Inhibition of cell adhesion and invasion was dose-
dependent in all three cell lines. To further analyze the 
effect of phenformin on motility and migration of ovarian 
cancer cells, the levels of expression of E–cadherin, Snail 
and VEGF were analyzed by Western blotting. After 24 
hours of treatment, phenformin increased expression of 
E-cadherin and decreased expression of snail and VEGF 
(Figure 5C). Collectively, these results demonstrate that 
phenformin inhibits the adhesion and invasion of ovarian 
cancer cells.
Phenformin decreases tumor growth in an 
orthotopic mouse model of serous OC
To validate the anti-tumorigenic potential of 
phenformin in vivo, we utilized an orthotopic high grade 
serous OC mouse model (M909) by injecting M909 
cells into the ovary bursa of female mice [23]. When 
tumors reached a size of 0.1 cm, mice were treated with 
phenformin (2 mg/kg/day, intraperitoneal) or vehicle 
(saline) for 4 weeks. Tumor growth during the treatment 
was monitored by palpation and calipers twice a week. 
After 4 weeks of treatment, the mice were euthanized, 
and the ovarian tumors were removed, photographed, and 
weighed. Phenformin significantly inhibited tumor weight 
and volume in the M909 mice (n=13 animals per group) 
by 64% and 68%, respectively as compared to the vehicle 
treated controls (p=0.01014, Figure 6A and 6B). During 
the treatment, the mice showed tolerance to phenformin 
and maintained normal activities. Regular weekly 
measurements yielded no significant changes in blood 
glucose (Figure 6C) or body weight (data not shown). 
Serum levels of VEGF were found to be decreased 
significantly by 23% in the M909 mice treated with 4 
weeks of phenformin compared to controls (Figure 6D).
To further confirm the anti-tumorigenic activity 
of phenformin in vivo, the expression of Ki-67, 
cleaved caspase 3, VEGF, phosphorylated-AMPK and 
phosphorylated-S6 in the ovarian tumor tissues was 
evaluated by immunohistochemistry (Figure 6E). Ki-
67 was significantly reduced following phenformin 
treatment compared to the controls, whereas phenformin 
increased the levels of cleaved caspase 3 in the 
treated mice. Consistent with our results in vitro, the 
expression of phosphorylated-AMPK was increased and 
phosphorylated-S6 was decreased in the mice treated with 
phenformin as compared to untreated mice. In addition, 
Figure 3: Phenformin activated AMPK and inhibited downstream targets of the mTOR pathway in the OC cells. 
The Hey, IGROV-1 and SKOV3 cells were treated with phenformin at different doses for 24 hours. Western immunoblotting was used to 
assess the effect of phenformin on AMPK and the mTOR pathways. A dose-dependent reduction in phosphorylated-S6 and an increase in 
phosphorylated-AMPK protein levels was seen for all three cell lines, after 24 hours of exposure. Each experiment was performed twice to 
assess for consistency of results.
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Figure 4: Phenformin induced cellular stress in ovarian cancer cells.  The Hey, IGROV-1 and SKOV3 cells were treated with 
phenformin at the indicated doses for 24 hours, and the ROS production was determined using the DCFH-DA assay. Phenformin increased 
the ROS level in a dose dependent manner. (A) The expression of cellular stress proteins (PERK, Ero1-1α, and PDI) was detected by 
western blotting after treatment of Phenformin for 24 hours. (B) *p < 0.05 and **p < 0.01.
Figure 5: Phenformin blocked cell adhesion and invasion in ovarian cancer cells. The Hey, IGROV-1 and SKOV3 cells were 
cultured for 24 hours and then treated with phenformin (0.01-2.5 mM) in a laminin coated 96 well plate or BME coated 96 transwell plate 
for 2 or 24 hours to assess adhesion and invasion in a plate reader. The data represents relative inhibition in each cell line. (A and B) The 
expression of VEGF, E–cadherin, and Snail were analyzed by Western blotting. (C) *p < 0.05 and **p < 0.01.
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we also found that phenformin significantly reduced the 
expression of VEGF in the M909 mice, suggesting that 
phenformin is able to inhibit cell invasion in vivo. These 
findings indicate that phenformin, like other biguanides, 
inhibits OC growth in vivo via activation of AMPK and 
inhibition of the mTOR pathway, both of which are critical 
signaling targets involved in proliferation and metabolism.
Phenformin inhibited proliferation of OC cells 
derived from patients
Primary cancer cell cultures have a greater capacity 
to predict realistic drug sensitivity than immortalized 
cancer cell lines. Thus, we further investigated the effects 
of phenformin on cell growth in primary cultures of 
OC cells using the MTT assay. Seven total primary cell 
cultures of OC were treated with different concentrations 
of phenformin for 72 hours. The results demonstrated that 
all seven primary cell cultures responded to phenformin 
and had achievable IC50 values (7/7, p=0.00001-0.015, 
IC50 range of 0.1 – 5 mM, Figure 7A and 7B).
DISCUSSION
Multiple pre-clinical studies have demonstrated 
that the metformin has anti-neoplastic properties for a 
number of different cancers, including OC [24, 50–54]. 
Recent studies have also found that phenformin, another 
biguanide, may behave similarly to metformin in the 
inhibition of cell and tumor growth but with potentially 
heightened efficacy, due to its non-dependence on organic 
cation transporters for entry into cells [40]. The anti-
tumorigenic activity of phenformin was first described 
in animal models in 1980 [45], and phenformin has since 
been found to have anti-neoplastic effects in breast, lung, 
prostate and colon cancers, among others. Phenformin has 
been shown to inhibit cellular proliferation [42, 55], induce 
apoptosis [43, 46], decrease cell cycle progression through 
increased expression of the cell cycle inhibitor p21 [55], 
suppress tumor growth and development in vivo [40, 41, 
44–46], activate AMPK and inhibit the mTOR pathway 
[40, 43], inhibit the mesenchymal-epithelial transition [56] 
as well as tumor migration [56] and angiogenesis [43]. 
Figure 6: Phenformin reduced tumor growth of orthotropic xenografts of serous OC. M909 cells were injected into left side 
of the ovarian bursa of 6–8 week old mice. When the tumors reached 0.1 cm in size (approximately 12 days after injection), the mice were 
treated with vehicle (control) or phenformin (2 mg/kg) once a day for 4 weeks. Tumor volume (A) and weight (B) were recorded during 
and after 4 weeks of treatment. Phenformin significantly inhibited tumor weight and volume in the M909 mice (n=13 animals per group) by 
64% and 68%, respectively as compared to the vehicle treated controls (p=0.01014). Phenformin did not affect serum glucose levels in the 
mice. (C) Changes in Ki-67, phosphorylated-AMPK, phosphorylated-S6, MMP9 and cleaved caspase 3 with phenformin treatment were 
assessed by immunohistochemistry in the ovarian tumor tissues. (D and E) Phenformin decreased Ki-67. MMP9, and phosphorylated-S6 
and increased caspase 3 and phosphorylated-AMPK in tumor tissues. *p<0.05; **p<0.01.
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Most importantly, phenformin has been shown to be more 
effective when compared to metformin in the inhibition of 
tumor development and growth in colon cancer cell lines 
[42], leukemia cell lines [57], and breast cancer cell lines 
and mouse models, without increased murine toxicity [41, 
43, 56, 58]. To date, the potential utility of phenformin in 
OC has not been well-studied.
We investigated the anti-neoplastic activity of 
phenformin in human OC cells, primary OC cultures and 
an orthotopic mouse model of high grade serous OC. 
Phenformin was found to inhibit cellular proliferation 
in a dose-dependent manner in all three human OC cell 
lines tested. It also exhibited more potent inhibition of 
cell proliferation and showed an enhanced affinity OCT1 
and OCT3 compared to metformin in OC cells. We 
demonstrated that induction of apoptosis, cellular stress 
and cell cycle G1 arrest were key components of the anti-
proliferative effects of phenformin in human OC cells, 
as evidenced by induced expression of annexin V and 
production of ROS as well as reduction of cyclin D and 
CDK4 expression. Phenformin was also found to inhibit 
adhesion and invasion in OC cells and reduced serum 
VEGF levels in M909 mice. Our results support previous 
results seen in other cancers including breast, colon and 
prostate [43, 46, 55, 56]. In addition, phenformin treatment 
(2mg/kg/day, intraperitoneal) led to profound inhibition 
of ovarian tumor growth in vivo. Our data supports prior 
studies that demonstate an anti-tumorigenic effect of 
phenformin in vitro and in vivo [40–46, 55–58].
Although biguanides have been shown to present 
anti-tumorigenic activity in many types of cancers 
including ovarian cancer, the detailed mechanisms of 
phenformin action against tumor have not been entirely 
defined. Several possible mechanisms related to the anti-
tumorigenic activity of biguanides could be explained 
by activation of AMPK, which is in turn leading to the 
inhibition of mTOR signaling pathway. Our recent results 
showed that AMPK is an ideal target for the prevention 
and treatment of ovarian cancer. In this study, phenformin 
activated AMPK and inhibited the mTOR pathway as was 
demonstrated by increased phosphorylation of AMPK and 
decreased phosphorylation of S6 expression in all three 
OC cell lines. As seen in the OC cell lines, the phenformin-
treated M909 ovarian tumors were shown to have 
decreased expression of Ki-67 and phosphorylated-S6 and 
an increase in phosphorylated AMPK and cleaved caspase 
3. Thus, similar to metformin [12, 59], phenformin’s anti-
tumorigenic effects in vivo may be through induction of 
cell cycle arrest and apoptosis via AMPK activation and 
inhibition of the downstream mTOR pathway.
AMPK activation by metformin is associated with 
increased oxidative stress leading to up-regulated cell 
cycle arrest and induction of apoptosis in breast cancer and 
leukemia [60, 61]. The anti-cancer effect of phenformin 
was related to complex I inhibition in the mitochondria 
and subsequent overproduction of reactive oxygen species 
(ROS) in colon cancer cells [47]. Treatment cancer cells 
with the ROS scavenger NAC significantly reduced the 
anti-cancer effect of phenformin, suggesting that anti-
cancer action of phenformin is closely associated with the 
production of ROS [47]. In this study, a dose dependent 
increase in ROS levels with phenformin was observed 
by DCFH-DA fluorescent assay in ovarian cancer cell 
lines. Phenformin was also associated with increased 
the expression of PERK, Ero1-1α and PDI, which are 
markers of oxidative stress associated with apoptosis [61]. 
This is consistent with proposed mechanism of action of 
phenformin involving AMPK activation leading to mTOR 
inhibition in ovarian cancer cells.
AMPK signaling exerts regulatory effects on 
cancer cell adhesion, migration and invasion, which is 
involved in different mechanisms including disruption of 
the mTOR, TGF-b, Pdlim5, CXCL12, NF-κB and Akt-
MDM2-Foxo3a pathways. Inhibition of melanoma cell 
invasion by metformin is correlated with modulation 
of expression of proteins involved in epithelial-
mesenchymal transition such as Slug, Snail, SPARC, 
fibronectin, and N-cadherin and with inhibition of MMP-
Figure 7: Phenformin inhibited cell proliferation in primary cultures of human OC. (A) Cell proliferation was assayed 
by MTT assay in seven primary cultures of human OCs after 72 hours of treatment with phenformin. (B) The IC50 value and clinical 
characteristics for the OC primary cultures.
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2 and MMP-9 activation [62]. We recently found that 
buformin significantly inhibits cell adhesion and invasion 
in endometrial cancer cells [63] and NT1014, a novel 
biguanide and AMPK activator, is able to reduce serum 
VEGF production and MMP expression in ovarian cancer 
tissues in a transgenic mouse model of ovarian cancer 
[50]. The current study further confirms that phenformin 
inhibits cell adhesion and invasion development through 
mediating the expression of epithelial–mesenchymal 
transition proteins and reducing VEGF and MMP 
productions in ovarian cancer. These findings bring new 
evidences to the understanding the antimetastatic effects 
of biguanides on ovarian cancer.
A major concern with phenformin is the increased 
risk of lactic acidosis seen in phenformin compared to 
metformin when used for the treatment of diabetes [64, 
65]. In our study, we did not observe any overt signs of 
toxicity or lactic acidosis in the M909 mice treated with 
phenformin. Lactic acid is formed because biguanides 
impair mitochondrial respiration via inhibition of complex 
I, which can result in a compensatory acceleration of 
glycolysis to counteract the reduced ATP production 
via oxidative phosphorylation [66]. Metformin is a less 
powerful inhibitor of the mitochondrial respiratory chain 
which may decrease its risk for lactic acidosis [67]. The 
increased incidence of lactic acidosis in phenformin may 
also occur because phenformin inhibits lactate oxidation 
[68, 69] and increases the release of lactate from muscle 
while metformin increases lactate oxidation and does not 
alter the release of lactate from muscle [70]. However, 
since phenformin is safer and has fewer side effects than 
many of the typical cytotoxic and targeted agents used 
for OC treatment, this potential risk may be tolerated if 
phenformin has greater anti-neoplastic properties than 
metformin. Other common side effects of phenformin, as 
for metformin, are symptoms of gastrointestinal distress, 
such as nausea and diarrhea; however, the incidence 
of gastrointestinal side effects are more common with 
metformin than phenformin [71].
Given that biguanides are cleared through renal 
secretion, nearly all episodes of lactic acidosis associated 
with biguanides have occurred in patients with renal 
dysfunction [72]. Careful patient selection and observation 
may allow this side effect to be minimized. Moreover, 
treating cells with a combination of phenformin and 
2-deoxyglucose or a lactate dehydrogenase (LDH) 
inhibitor, has been found to avoid the development of 
lactic acidosis [73]. In addition to reduction of lactic 
acidosis, combination treatment with phenformin and 
a LDH inhibitor led to increased inhibition of cell 
proliferation [42, 73, 74], suggesting that this may be a 
novel cancer treatment strategy for increased efficacy and 
reduced toxicity of phenformin.
One of the criticisms of the in vitro studies of 
metformin in cancer cell lines is that supra-physiological 
doses are needed to show an anti-proliferative effect, 
although clinically relevant doses have successfully 
inhibited tumor growth in animal cancer models [52, 
75]. This was thought to be related to the relatively low 
expression of OCT 1 and 3 in solid tumors and cancer 
cell lines [76]. Given that phenformin is more lipophilic 
and does not need these transporter proteins to enter 
cells, it has been hypothesized that phenformin may 
be an improvement over metformin, in that it will have 
the same beneficial metabolic effects and potentially be 
better taken up by tumor cells. However, our in vitro 
studies as well as those of others [42–44, 46, 56, 58] 
still required supra-physiological doses of this drug in 
culture to achieve IC50 growth inhibition. Thus, the 
differences in the low expression of OCT 1 and 3 does 
not explain the increased dose needed to demonstrate 
an effect in vitro, and alternatively, this may be related 
to the hyperglycemic concentrations typically used to 
maintain and grow cancer cell lines in culture. In support 
of this, lower and more physiological concentrations of 
both metformin and phenformin have been found to 
decrease OC cell proliferation under normaglycemic 
versus hyperglycemic conditions [30]. For our M909 
orthotopic OC mouse model, a clinically relevant dose 
for phenformin (2mg/kg/day, intraperitoneal) was used 
and proved to be effective in the inhibition of tumor 
growth.
In summary, the results from this study show that 
phenformin is a novel metabolic therapy that causes 
significant inhibition of OC cell proliferation in vitro and 
has anti-tumorigenic activity in vivo against OC. Given 
the increased risk of lactic acidosis, the risk/benefit ratio 
clearly favors metformin for the treatment of diabetes; 
however, this may not hold true for the treatment of 
cancer if phenformin was found to have superior anti-
tumorigenic activity. Thus, our future work will entail 
a head-to-head comparison of phenformin against 
metformin in our orthotopic mouse model of serous OC. 
Lastly, an unanswered but important question in regards 
to phenformin and other biguanide treatment is whether 
these agents will be efficacious in all OC patients or 
more specifically beneficial in those that are obese or 
diabetic, similar to what has also been shown in breast 
and lung cancer mouse models [52, 77] and our own work 
in OC [78]. Given this, we plan to study the efficacy of 
phenformin versus metformin in our orthotopic OC mouse 
model under obese and lean conditions. Interestingly, 
metformin treatment has been previously found to elicit 
greater reductions in tumor growth in normoglycemic 
versus hyperglycemic conditions in a syngeneic OC 
mouse model [30], suggesting that diet-induced obesity 
versus hyperglycemia are not interchangeable and instead 
are distinct in their impact on metformin response. A better 
understanding of the interplay between the metabolic 
milieu and biguanide treatment is critically needed for the 
further development of these drugs in the treatment and 
prevention of all cancers, including OC.
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MATERIALS AND METHODS
Cell culture and reagents
Three OC cell lines, SKOV3, Hey and IGROV-1, 
were used for the experiments. The SKOV3 cells were 
maintained in DMEM/F12 medium with 10% fetal 
bovine serum (FBS). The IGROV-1 cells were maintained 
in RPMI 1640 with 10% FBS. The Hey cell line was 
maintained in RPMI 1640 with 5% FBS. All medium was 
supplemented with 100 U/ml of penicillin and 100 ug/ml 
of streptomycin. The cells were cultured in a humidified 
5% CO2 at 37°C. Phenformin was purchased from Sigma 
(St. Louis, MO). MTT (3-(,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), RNase A and RIPA buffer 
were purchased from Sigma (St. Louis, MO). Antibodies 
to phosphorylated-AMPK (Thr172), phosphorylated-S6 
(Ser 235/236), β-actin, pan-AMPK and pan-S6 were 
obtained from Cell Signaling Technology (Beverly, MA). 
The Annexin V FITC kit was purchased from BioVision 
(Mountain View, CA). Enhanced chemiluminescence 
Western blotting detection reagents were purchased from 
Amersham (Arlington Heights, IL). All other chemicals 
were purchased from Sigma.
Cell proliferation assays
The SKOV3, Hey and IGROV-1 cells were plated 
and grown in 96-well plates at a concentration of 4000 
cells/well for 24 hours. The cells were then treated with 
various concentrations of phenformin for a period of 72 
hours. After the addition of MTT dye (5 mg/ml), the 96-
well plates were incubated for an additional hour at 37°C. 
The MTT reaction was terminated through the addition 
of 100 uL of DMSO. The plates were read by measuring 
absorption at 595 nm with a Microplate Reader (Tecan, 
Morrisville, NC). The effect of phenformin was calculated 
as a percentage of control cell growth obtained from PBS 
(1%) treated cells grown in the same 96-well plates. 
Each experiment was performed in triplicate to assess for 
consistency of results.
Cell cycle assay
The effect of phenformin on cell cycle progression 
was assessed using Cellometer (Nexcelom, Lawrence, 
MA). Cells were plated at a density of 2.5 x105 cells/well 
in 6-well plates overnight and then treated with varying 
concentrations of phenformin for 24 hours. Cells were 
collected by 0.05% trypsin (Gibco, Grand Island, NY), 
washed with phosphate-buffered saline (PBS) solution, 
fixed in a 90% methanol solution and then stored at -20°C 
until cell cycle analysis was performed. On the day of 
analysis, the cells were washed with PBS and centrifuged, 
re-suspended in 50 ul RNase A solution (250 ug/ml) 
with 10 mM EDTA, followed by incubation for 30 min 
at 37°C. After incubation, 50 μl of propidium iodide (PI) 
staining solution (2 mg/ml PI, 0.1 mg/ml Azide and 0.05% 
Triton X-100) was added to each tube, and the cells were 
incubated for 10 min in the dark. The cells were then 
assessed by Cellometer. The results were analyzed using 
FCS4 express software (Molecular Devices, Sunnyvale, 
CA). Each experiment was performed in triplicate to 
assess for consistency of results.
Apoptosis assay
The effect of phenformin on cell apoptosis was 
evaluated by using the Annexin-V FITC Apoptosis 
Detection Kit. The cells were plated in 6 well plates (2.5 
x105 cells/well) for 24 hours and then treated with varying 
concentrations of phenformin. The cells were collected by 
0.25% trypsin without EDTA. After washing with PBS, 
cells were resuspended in 100 ul of Annexin-V and PI 
dual-stain solution (0.1 ug of Annexin-V FITC and 1 ug 
of PI) for 15 min in the dark. Apoptotic cells were detected 
by Cellometer. The results were analyzed by FCS4 express 
software. All experiments were performed in triplicate to 
assess for consistency of response.
Adhesion assay
Each well in a 96-well plate was coated with 100 
ul laminin-1 (10 ug/ml) and incubated at 37°C for 1 hour. 
This fluid was then aspirated, and 200ul blocking buffer 
was added to each well for 45-60 min at 37°C. The wells 
were then washed with PBS, and the plate was allowed to 
chill on ice. To each well, 2.5 x 103 cells were added with 
PBS and varying concentrations of phenformin directly. 
The plate was then allowed to incubate at 37°C for 2 hours. 
After this period, the medium was aspirated, and cells 
were fixed by directly adding 100 ul of 5% glutaraldehyde 
and incubating for 30 min at room temperature. Adhered 
cells were then washed with PBS and stained with 100 ul 
of 0.1% crystal violet for 30 minutes. The cells were then 
washed repeatedly with water, and 100 ul of 10% acetic 
acid was added to each well to solubilize the dye. After 5 
minutes of shaking, the absorbance was measured at 570 
nm using a micro-plate reader from Tecan (Morrisville, 
NC). Each experiment was repeated at least twice for 
consistency of response.
Invasion assay
Cell invasion assays were performed using 96-
well HTS transwells (Corning Life Sciences, Durham, 
NC) coated with 0.5-1X BME (Trevigen, Gaithersburg, 
MD). The SKOV3, Hey and IGROV-1 (50,000/well) 
were starved for 12 hours and then seeded in the upper 
chambers of the wells in 50 μl FBS-free medium. The 
lower chambers were filled with 150 μl regular medium 
with phenformin. The plate was incubated for 24 hours 
at 37°C to allow invasion into the lower chamber. After 
washing the upper and lower chambers with PBS, 100 ul 
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Calcein AM solution was added into the lower chamber 
and incubated at 37°C for 30-60 min. The lower chamber 
plate was measured by the plate reader for reading 
fluorescence at EX/EM 485/520 nM. Each experiment was 
repeated at least twice for consistency of response.
Western immunoblotting
The SKOV3, Hey, and IGROV-1 cells were plated 
at 2.5 x105 cells/well in 6 well plates in their appropriate 
media and were treated for 24 hours with phenformin. 
Cell lysates were prepared in RIPA buffer (1% NP40, 0.5 
sodium deoxycholate and 0.1% SDS) plus PhosStop. Equal 
amounts of protein were separated by gel electrophoresis 
and transferred onto a PVDF membrane. The membrane 
was blocked with 5% nonfat dry milk and then incubated 
with a 1:1000 dilution of primary antibody overnight at 
4°C. The membrane was then washed and incubated with a 
secondary peroxidase conjugated antibody for 1 hour after 
washing. Antibody binding was detected using an enhanced 
chemiluminescence detection buffer and the Alpha Innotech 
Imaging System (San Leandro, CA). After developing, the 
membrane was re-probed using antibody against α-tubulin 
or β-actin as a control for equal loading. Each experiment 
was repeated three times to assess for consistency of results.
Measurement of VEGF levels in serum
The VEGF concentration in the serum of mice after 
exposure to phenformin was measured with a VEGF 
ELISA kit (DVE00, R&D Systems, Minneapolis, MN), 
according to the manufacturer’s instructions. 10 ul of 
serum from phenformin and control groups (6 samples /
per group) was used in the assay. The optical density at 
570 nm of each well was measured using a FLUOstar 
OMEGA reader (Cary, NC).
Reactive oxygen species (ROS) assay
The alteration of total production of reactive 
oxygen species caused by phenformin was measured 
using a DCFH-DA fluorescent dye. The SKOV3, Hey 
and IGROV-1 cells (1.0 × 104 cells/well) were seeded in 
black 96-well plates. After 24 hours, the cells were treated 
with phenformin (0.1 to 5 mM) for 4 hours to induce ROS 
generation. After the cells were incubated with DCFH-
DA (20 μM) for 30 min, the fluorescence was monitored 
at an excitation wavelength of 485 nm and an emission 
wavelength of 530 nm using a plate reader (Tecan). All 
experiments were performed at least twice to assess for 
consistency of response.
Primary OC cell culture
Seven tumor specimens were sampled from 
patients undergoing surgery for high grade serous OC 
at an academic institution. The protocol was reviewed 
and approval granted by the Institutional Review Board. 
Freshly obtained tissues were washed three times with 
Hank's Buffered Salt Solution and then gently minced by 
scissors in DMEM/F12 medium containing 10% FBS. 
These tissues were then digested in 0.2% collagenase 
IA, 100 U/ml penicillin and anti-anti for 30-60 min in a 
37°C water bath with shaking. After two centrifugations 
with PBS solution, cells were re-suspended and diluted 
to 1x105 cells/ml with DMEM/F12 medium. 2x104 cells/
well were seeded into 96-well plates and incubated for 24 
hours before treatment with phenformin. Cell proliferation 
was measured by MTT assay after 72 hours of phenformin 
treatment.
Orthotropic xenografts of serous OC
The K18-gT121+/-p53 fl/flBrca1 fl/fl (KpB) mouse 
model is a high grade serous OC mouse model that 
specifically and somatically deletes the tumor suppressor 
genes, Brca1 and p53, and inactivates the retinoblastoma 
(Rb) proteins in adult ovarian surface epithelial cells 
(KpB mouse model) [48]. As an extension of this model, 
we have established an ovarian tumor cell line from one 
of the KpB mice (M909). Upon re-injection of these 
tumor cells into the ovarian bursa of female mice, we 
have developed a more aggressive variant of the KpB 
model [79]. For the evaluation of phenformin’s in vivo 
effects, M909 cells (1X106 cells/5 μl) were injected into 
the left side of the ovarian bursa of 6–8 week old mice. 
All mice were handled according to protocols approved 
by the Institutional Animal Care and Use Committee 
(IACUC). Twenty-six mice were injected with the M909 
cells and then randomly divided into the vehicle (i.e. 
control) or phenformin group. Phenformin (2 mg/kg/day, 
intraperitoneal) and vehicle treatment was initiated after 
palpation of a 0.1 cm tumor in the mice. Tumor size was 
checked twice a week by caliper measurement. Tumor 
volume was calculated using the following equation 
(width2 × length)/2. All mice were euthanized after four 
weeks of phenformin or vehicle treatment. At sacrifice, 
mice were weighed and blood samples were taken. Half 
of the ovarian tumor was snap-frozen and stored at −80°C, 
and the other half was fixed in 10% neutral-buffered 
formalin and paraffin embedded.
Immunohistochemistry
Five micrometer paraffin sections, prepared from the 
ovarian tumors of the M909-injected mice, were used for 
immunohistochemical analysis. Staining procedures were 
performed at the IHC Mice Core Facility. The following 
primary antibodies were used: Ki-67, cleaved caspase-3, 
MMP9, phosphorylated-AMPK and phosphorylated-S6. 
Further processing was carried out using the ABC-Staining 
Kits (Vector Labs, Burlingame, CA) and hematoxylin. 
Immunochemistry slides were scanned, analyzed and 
scored by Aperio and ImageScope software (Vista, CA).
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Statistical analysis
Data were presented as mean ± standard error of 
the mean. Statistical analysis of the differences between 
the groups was determined with the two-sided unpaired 
Student’s t-test using GraphPad software (La Jolla, CA 
USA). A value of p<0.05 was considered significant.
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